Menu Search
Equities

Perpetua Medical AB (publ)

PERP B:STO

Perpetua Medical AB (publ)

Actions
  • Price (SEK)0.175
  • Today's Change0.004 / 2.34%
  • Shares traded100.87k
  • 1 Year change+6.06%
  • Beta2.0663
Data delayed at least 15 minutes, as of Sep 20 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year Perpetua Medical AB (publ) had relatively flat revenues (10.11m to 9.94m), though the company grew net income from a loss of 19.16m to a smaller loss of 18.28m. A reduction in the selling, general and administrative costs as a percentage of sales from 150.17% to 145.66% was a component in the net income growth despite flat revenues.
Gross margin-65.03%
Net profit margin-134.27%
Operating margin-139.12%
Return on assets-54.70%
Return on equity-74.21%
Return on investment-74.20%
More ▼

Cash flow in SEKView more

In 2023, cash reserves at Perpetua Medical AB (publ) fell by 5.16m. Cash Flow from Financing totalled 12.12m or 121.93% of revenues. In addition the company used 16.41m for operations while cash used for investing totalled 865.25k.
Cash flow per share-0.0499
Price/Cash flow per share--
Book value per share0.095
Tangible book value per share0.095
More ▼

Balance sheet in SEKView more

Perpetua Medical AB (publ) appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio6.58
Quick ratio6.39
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.